Enhancement of factor VIIa haemostatic efficacy by formulation with PEGylated liposomes (Q45876598)

17 December 2017

title

Enhancement of factor VIIa haemostatic efficacy by formulation with PEGylated liposomes (English)

1 reference

17 December 2017

author name string

R Yatuv

1

1 reference

17 December 2017

I Dayan

2

1 reference

17 December 2017

L Carmel-Goren

3

1 reference

17 December 2017

M Robinson

4

1 reference

17 December 2017

I Aviv

5

1 reference

17 December 2017

M Goldenberg-Furmanov

6

1 reference

17 December 2017

M Baru

7

1 reference

17 December 2017

publication date

3 April 2008

1 reference

17 December 2017

published in

Haemophilia

1 reference

17 December 2017

volume

14

1 reference

17 December 2017

issue

3

1 reference

17 December 2017

page(s)

476-483

1 reference

17 December 2017

Successful use of recombinant factor VIIa in patient with severe haemophilia A during synovectomy

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2008.01741.X

A randomized, double-blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors. rFVIIa Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2008.01741.X

Efficacy and safety of recombinant factor VIIa in the prophylaxis of bleeding in various surgical procedures in hemophilic patients with factor VIII and factor IX inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2008.01741.X

Dosing with recombinant factor viia based on current evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2008.01741.X

Pharmacokinetics and pharmacodynamics of recombinant factor VIIa

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2008.01741.X

A new approach to treatment of bleeding episodes in young hemophilia patients: a single bolus megadose of recombinant activated factor VII (NovoSeven).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2008.01741.X

Dose optimization of recombinant factor VIIa for control of mild to moderate bleeds in inhibitor patients: Improved efficacy with higher dosing

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2008.01741.X

Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society Registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2008.01741.X

Complications associated with the treatment of haemophiliacs with inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2008.01741.X

Improved hemostasis with superactive analogs of factor VIIa in a mouse model of hemophilia A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2008.01741.X

A variant of recombinant factor VIIa with enhanced procoagulant and antifibrinolytic activities in an in vitro model of hemophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2008.01741.X

Factor VIIa analogue (V158D/E296V/M298Q-FVIIa) normalises clot formation in whole blood from patients with severe haemophilia A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2008.01741.X

Effect of recombinant factor VIIa variant (NN1731) on platelet function, clot structure and force onset time in whole blood from healthy volunteers and haemophilia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2008.01741.X

Prolonged bleeding-free period following prophylactic infusion of recombinant factor VIII reconstituted with pegylated liposomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2008.01741.X

Liposomal approach towards the development of a longer-acting factor VIII.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2008.01741.X

Whole blood clot formation phenotypes in hemophilia A and rare coagulation disorders. Patterns of response to recombinant factor VIIa

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2008.01741.X

Mechanism of action of factor VIIa in the treatment of coagulopathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2008.01741.X

Whole blood coagulation thrombelastographic profiles employing minimal tissue factor activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2008.01741.X

High dose factor VIIa improves clot structure and stability in a model of haemophilia B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2008.01741.X

The haemostatic plug in haemophilia A: a morphological study of haemostatic plug formation in bleeding time skin wounds of patients with severe haemophilia A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2008.01741.X

The role of recombinant factor VIIa (FVIIa) in fibrin structure in the absence of FVIII/FIX.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2008.01741.X

Mechanism of action of recombinant activated factor VII: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2008.01741.X

10.1111/J.1365-2516.2008.01741.X

21 January 2018

Identifiers

DOI

1 reference

17 December 2017

PubMed ID

18393980

1 reference

17 December 2017